- Home
- CRVS vs CTNM Comparison
CRVS vs CTNM Comparison
Compare CRVS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- CTNM
- Stock Information
- Founded
- CRVS 2014
- CTNM 2009
- Country
- CRVS United States
- CTNM United States
- Employees
- CRVS N/A
- CTNM N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- CTNM
- Sector
- CRVS Health Care
- CTNM
- Exchange
- CRVS Nasdaq
- CTNM Nasdaq
- Market Cap
- CRVS 305.4M
- CTNM 248.7M
- IPO Year
- CRVS 2016
- CTNM 2024
- Fundamental
- Price
- CRVS $5.55
- CTNM $9.94
- Analyst Decision
- CRVS Strong Buy
- CTNM Strong Buy
- Analyst Count
- CRVS 4
- CTNM 4
- Target Price
- CRVS $15.00
- CTNM $22.75
- AVG Volume (30 Days)
- CRVS 461.1K
- CTNM 206.5K
- Earning Date
- CRVS 08-07-2025
- CTNM 08-05-2025
- Dividend Yield
- CRVS N/A
- CTNM N/A
- EPS Growth
- CRVS N/A
- CTNM N/A
- EPS
- CRVS N/A
- CTNM N/A
- Revenue
- CRVS N/A
- CTNM N/A
- Revenue This Year
- CRVS N/A
- CTNM N/A
- Revenue Next Year
- CRVS N/A
- CTNM N/A
- P/E Ratio
- CRVS N/A
- CTNM N/A
- Revenue Growth
- CRVS N/A
- CTNM N/A
- 52 Week Low
- CRVS $2.54
- CTNM $3.35
- 52 Week High
- CRVS $10.00
- CTNM $20.55
- Technical
- Relative Strength Index (RSI)
- CRVS 69.70
- CTNM 79.45
- Support Level
- CRVS $5.03
- CTNM $6.56
- Resistance Level
- CRVS $5.81
- CTNM $6.95
- Average True Range (ATR)
- CRVS 0.32
- CTNM 0.82
- MACD
- CRVS 0.09
- CTNM 0.31
- Stochastic Oscillator
- CRVS 85.22
- CTNM 85.28
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.